Background: Chlorhexidine gluconate (CHG) is a topical antiseptic widely utilized for daily bathing in pediatric and adult populations and has been shown to be effective in reducing healthcare-associated infections (HAIs). However, the Centers for Disease Control (CDC) recommends using it with caution in patients less than 2 months of age. However, as HAIs remain a significant problem in this patient population, a study is ongoing at our institution addressing these concerns. The clinical chemistry team was recruited to help characterize CHG levels for this population. Preliminary validation results are reported here. Methods: A LC-MS/MS method was developed to quantitate CHG plasma levels. Linearity was determined from linear regression analysis (n = 7) of plasma levels spiked at 500ng/mL and diluted to 5 ng/mL. Precision was assessed by replicate measurement (n = 5) of CHG in spiked patient pools across the concentration range of 10 to 500 ng/mL. Adult, medical intensive care unit (MICU), and neonatal intensive care unit (NICU) patient pools were created (n = 3) from discarded clinical specimens. Matrix effect was measured by spiking in CHG in the pool and recovery was subsequently measured at 5, 20 and 100 ng/mL. Results: The calibration curve showed excellent correlation between the concentration and signal response (r = .97). Preliminary assay imprecision (%CV) was assessed at CHG concentrations of 500, 200, 100, 20, and 10 ng/ mL. The mean coefficient of variation (%CV) using the LC-MS/MS method at 500, 200, 100, 20, and 10 ng/mL were 2.9%, 4.9%, 4.3%, 17.4%, and 59.4%, respectively. Randomly selected clinically discarded specimens also revealed high background CHG exposure (>50 ng/mL). Baseline adult, MICU, and NICU pools showed >20 ng/ mL CHG levels. The adult, MICU, and NICU pools showed comparable recovery across the different types of pools. Average recovery (%) ranged 37%-41%, 31%-37%, and 80%-115% at 5, 20, and 100 ng/mL, respectively. Conclusion: We have developed a LC-MS/MS method that allows us to quantitate chlorhexidine in patients younger than 2 months. We also show that detectable levels were common in neonates less than 2 months old.
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Validation of Thromboxane A2 Analogue U46619 in Whole Blood Platelet Aggregation to Diagnose Platelet Disorders
Xi Zhang, Morayma Reyes-Gil; Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY Thromboxane A2 analogue U46619 is conventionally used in platelet-rich plasma aggregometry (optical method) to diagnose platelet disorders. However, a significant proportion of the normal population is nonsensitive to U46619 (~10-20%). Noteworthy, a protocol for the use of U46619 in whole blood aggregometry (impedance method) is yet to be established and published. Herein we aimed to validate the use of U46619 in whole blood aggregometry, and improve its sensitive and specificity to detect secretion problems. Serial doses of U46619 (calculated based on hematocrit adjustment) where tested in whole blood from normal donors. After an optimal concentration was chosen, 45 normal donor samples were tested to establish a reference range. Also, we tested if the addition of the chemiluminescence reagents (luciferase and luciferin) to detect ATP secretion improves the sensitivity and specificity. More than 100 cases were analyzed using U46619 as part of a panel including other common platelet agonists such as ADP, collagen, arachidonic acid, thrombin, and ristocetin. The addition of the chemiluminescence reagents significantly improved the platelet aggregation response in normal donors: in the cohort without chemiluminescence reagents, approximately 10% were nonsensitive (no aggregation detected), whereas in the cohort with chemiluminescence reagents the average aggregation response (as measure in ohms) doubled. Therefore, the specificity is 98%, as determined by the number of cases diagnosed as "normal" or non-clinically significant but showed abnormal platelet aggregation response to U46619. The sensitivity was also high, 92%, as determined by the number cases with abnormal response that were diagnosed with a platelet disorder using further confirmatory testing (platelet electron microscopy or molecular testing). In summary, U46169 in whole blood aggregometry is highly sensitive and specific for detection of platelet disorders, in particular storage pool disorders. Furthermore, U46619 is extremely useful to differentiate aspirin-like defects from secretion problems. Finally, we will present examples of U46619-induced platelet aggregation and ATP secretion in a series of common platelet disorders, including Bernard-Soulier, Glanzmann thrombasthenia, aspirin-like defects, and storage pool disorders, as well as other rare platelet disorders such as Rett syndrome, Paris-Trousseau syndrome, and Noonan syndrome.
